Reducing cascades while maintaining our commitment to high-quality care requires equipping patients and clinicians with the information, tools, and support to embrace uncertainty.
ABSTRACT
Cascades of care are common and can lead to significant harms for patients, clinicians, and the health care system at large. In this commentary, we argue that there are 2 ways to reduce cascades: decrease the use of unnecessary services that often initiate cascades (ie, close the floodgates) and mitigate cascades once they begin (ie, slow the flow through the floodgates). So far, most efforts to address cascades have focused on identifying, measuring, and educating clinicians on low-value services, with only modest success. We explore potential solutions for both closing the floodgates and slowing a cascade once the floodgates have been opened, including information to assist patients and clinicians in making better decisions, relationships that enable shared decision-making, and policy changes. Ultimately, reducing cascades while maintaining our commitment to high-quality care requires equipping patients and clinicians with the information, tools, and support needed to embrace uncertainty.
Am J Manag Care. 2021;27(5):178-180. https://doi.org/10.37765/ajmc.2021.88630
Takeaway Points
Reducing cascades while maintaining our commitment to high-quality care requires equipping patients and clinicians with the information, tools, and support to embrace uncertainty.
The term cascades of care refers to a succession of medical services that are often fueled by the desire to avoid even the smallest risk of a serious condition.1 They can follow from incidental or marginal findings on screening and diagnostic tests, some of which are themselves of low value. Regardless of their origins, they can be difficult to stop once the floodgates are opened, often leading to harms for patients, clinicians, and the health care system at large.
In certain cases, further evaluation of unexpected findings can serve a useful purpose, such as uncovering a dangerous yet treatable cancer.2 More often, these pursuits are ultimately futile and costly. For example, consider an unwarranted preoperative electrocardiogram prior to a low-risk procedure like cataract surgery, where an inconclusive result may prompt additional referrals, diagnostic testing, and catheterization that rarely confirms significant cardiovascular disease.3 The process can be emotionally and physically exhausting for patients without offering them any real benefits.
Cascades of care are extremely common. In a recent survey of US internists, more than 99% of respondents reported that they had experienced cascades from incidental findings. One-third experienced cascades with no clinically important or intervenable outcome on at least a monthly basis. Notably, more than half of respondents said cascades led to physical, psychological, and financial harm to patients and wasted time, frustration, and anxiety for physicians.2,4
There are 2 ways to reduce cascades: (1) decrease the use of unnecessary services that often initiate cascades (ie, close the floodgates) and (2) mitigate cascades once they begin (ie, slow the flow through the floodgates). Both are critical to preventing these floods from causing catastrophic damage.
Closing the Floodgates
So far, most efforts to address low-value care, including the Choosing Wisely campaign and the US Preventive Services Task Force (USPSTF) rating system, have focused on identifying, measuring, and educating patients and clinicians on low-value services.5-7 However, these initiatives have had only modest success in reducing the use of low-value care.8 One reason for this might be the lack of policies that incentivize clinicians or patients to put recommendations into practice. Of note, Section 4105 of the Patient Protection and Affordable Care Act authorizes Medicare plans to remove coverage for preventive care services that are deemed harmful or unnecessary by the USPSTF (ie, D rating).9 By pushing implementation of this provision, the new administration has an opportunity to meaningfully address the prevalence of low-value care.
Closing the floodgates makes sense when it is possible to identify a specific service as low value. However, this can be difficult in many cases, given the poor consensus around how to incorporate clinical nuance, patient preferences, and cost-benefit trade-offs into this designation.10 Moreover, cascades are often triggered by initial tests that are clinically appropriate.4 Given these factors, it is also important to mitigate cascades once they begin.
Slowing the Flow Through the Floodgates
Slowing the flow may be more challenging; it is easier to avoid discovering an “incidentaloma” than to unsee it. Clinicians order that second or third test because they fear missing something important, fear being sued, feel an obligation to follow practice and community norms, or believe they are responding to patient preferences.2,11 To slow a cascade once the floodgates have been opened, we need (1) information to assist patients and clinicians in making better decisions, (2) relationships that enable shared decision-making, and (3) policy changes.
Information to help patients and clinicians make better decisions. Physicians often feel frustrated but compelled to pursue additional testing for incidental findings when results are unfamiliar and are not accompanied by information to contextualize their clinical importance.11 Yet, cascades may occur even when such information is provided. For example, a multicenter study showed that including data on the prevalence of age- and sex-specific abnormalities in healthy adults on spine imaging reports (thereby “normalizing” these abnormalities) did not decrease subsequent spine-related utilization.12
This speaks to the importance of providing the right information at the right time. In the spine imaging study, the information included in reports was based on population-level estimates, making it challenging to generalize to individual patients, and did not include recommendations for follow-up. For information to be useful to clinicians, it should be clear, specific, and provided at the point of care. The information should also be guided by high-quality evidence rather than just expert opinion, which tends to be more conservative and promote cascades. To this end, there is a need for more research on when a laboratory “abnormality” does or does not require further testing and on best practices for evaluation of various incidentalomas.
In the wake of the 21st Century Cures Act, patients increasingly have access to their test results, and any deviation from “normal” can provoke anxiety. Ideally, test results would be presented alongside interpretative comments in language that is easily understood. Another solution might be allowing patients to review imaging results with radiologists directly. In general, the public should be better sensitized to the idea that medical tests and procedures carry harms and that attempts to “prevent” devastating but rare outcomes can have risks of their own.
Trusting patient-clinician relationships. Using reliable, point-of-care information, we can leverage trusting patient-clinician relationships to engage patients in shared decision-making to minimize the harms of cascades. When faced with a dilemma (eg, after an incidental finding is found, should testing be pursued to rule out a rare but life-threatening diagnosis?), clinicians need to understand and factor in what is important to patients. In an open conversation, clinicians can explain the clinical implications of findings and potential harms and benefits of further testing; similarly, patients can share their concerns and reasons for and against further testing. These conversations should start early—when deciding to order a test in the first place—and may reassure clinicians who pursue cascades due to fears of litigation.
Clinicians need training and resources to navigate these conversations. Although most clinicians report having conversations about cascades with patients, they are often limited to specific use cases (eg, pulmonary nodules incidentally found on chest radiography).2 Education on overuse should be baked into the medical curriculum such that clinicians feel comfortable talking to patients about uncertainty. Decision aids and scripts can be integrated into the electronic health record to help guide these conversations.
Policy changes. It is important to consider the legal and policy context in which these conversations are happening. For instance, the shift to value-based payment may incentivize clinicians to reduce unnecessary medical tests and treatments, although evidence remains mixed.13 Alongside efforts to reduce the number of low-value tests ordered, future models should invest in point-of-care solutions to stem low-value cascades once they are triggered.
Medical malpractice reform is another solution that is appealing in theory, although reforms to date have had limited impact on low-value care utilization. A fear of malpractice lawsuits can propel cascades14—in one study, the possibility of a lawsuit increased the intensity of care that patients received, although this extra testing and treatment did not improve outcomes.15 One promising approach is the creation of “safe harbor” laws that protect clinicians from liability if they adhere to clinical practice guidelines based on rigorous evidence.16 There is also evidence that specific communication behaviors, such as educating patients on the purpose of tests and procedures, soliciting patients’ opinions, and checking understanding, are associated with fewer malpractice claims.17 Thus, safe harbor laws that encourage clinicians to follow guidelines and explain the context and implications of incidental findings may mitigate cascades motivated by legal concerns.
Conclusions
Ultimately, reducing cascades while maintaining our commitment to high-quality care requires becoming more comfortable with uncertainty.18 Although the increasing attention to low-value care is an important step forward, to really stop the flood, we need strategies that provide patients and clinicians with the information, tools, and support to embrace the uncertainty inherent in medicine.
Author Affiliations: Harvard Medical School (PC, IG), Boston, MA; Department of Internal Medicine and Center for Value-Based Insurance Design (AMF), Ann Arbor, MI; Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women’s Hospital (IG), Boston, MA.
Source of Funding: None.
Author Disclosures: Dr Fendrick has been a consultant for AbbVie, Amgen, Centivo, Community Oncology Alliance, Covered California, EmblemHealth, Exact Sciences, Freedman Health, GRAIL, Harvard University, Health & Wellness Innovations, Health at Scale Technologies, MedZed, Merck, Montana Health Cooperative, Penguin Pay, Risalto, Sempre Health, State of Minnesota, US Department of Defense, Virginia Center for Health Innovation, Wellth, Yale–New Haven Health System, and Zansors; has performed research for the Agency for Healthcare Research and Quality, Arnold Ventures, Boehringer Ingelheim, Gary and Mary West Health Policy Center, National Pharmaceutical Council, Patient-Centered Outcomes Research Institute, PhRMA, Robert Wood Johnson Foundation, and State of Michigan/CMS; and holds outside positions as co-editor-in-chief of The American Journal of Managed Care®, member of the Medicare Evidence Development & Coverage Advisory Committee, and partner in V-BID Health, LLC. Dr Ganguli has received a grant from the Agency for Healthcare Research and Quality on cascades of care and has presented on cascades at conferences. Ms Chandrashekar reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (PC, AMF, IG); drafting of the manuscript (PC, AMF, IG); critical revision of the manuscript for important intellectual content (PC, AMF, IG); and supervision (AMF, IG).
Address Correspondence to: Ishani Ganguli, MD, MPH, Brigham and Women’s Hospital, 1620 Tremont St, 3rd Floor, Boston, MA 02120. Email: iganguli@bwh.harvard.edu.
REFERENCES
1. Mold JW, Stein HF. The cascade effect in the clinical care of patients. N Engl J Med. 1986;314(8):512-514. doi:10.1056/NEJM198602203140809
2. Ganguli I, Simpkin AL, Lupo C, et al. Cascades of care after incidental findings in a US national survey of physicians. JAMA Netw Open. 2019;2(10):e1913325. doi:10.1001/jamanetworkopen.2019.13325
3. Ganguli I, Lupo C, Mainor AJ, et al. Prevalence and cost of care cascades after low-value preoperative electrocardiogram for cataract surgery in fee-for-service Medicare beneficiaries. JAMA Intern Med. 2019;179(9):1211-1219. doi:10.1001/jamainternmed.2019.1739
4. Korenstein D, Chimonas S, Barrow B, Keyhani S, Troy A, Lipitz-Snyderman A. Development of a conceptual map of negative consequences for patients of overuse of medical tests and treatments. JAMA Intern Med. 2018;178(10):1401-1407. doi:10.1001/jamainternmed.2018.3573
5. Choosing Wisely. Accessed December 22, 2020. https://www.choosingwisely.org
6. U.S. Preventive Services Task Force Ratings. U.S. Preventive Services Task Force. Accessed April 1, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/us-preventive-services-task-force-ratings
7. Ganguli I, Lupo C, Mainor AJ, et al. Assessment of prevalence and cost of care cascades after routine testing during the Medicare annual wellness visit. JAMA Netw Open. 2020;3(12):e2029891. doi:10.1001/jamanetworkopen.2020.29891
8. Mafi JN, Reid RO, Baseman LH, et al. Trends in low-value health service use and spending in the US Medicare fee-for-service program, 2014-2018. JAMA Netw Open. 2021;4(2):e2037328. doi:10.1001/jamanetworkopen.2020.37328
9. Compilation of Patient Protection and Affordable Care Act. HHS. 2010. Accessed April 1, 2021. https://www.hhs.gov/sites/default/files/ppacacon.pdf
10. Beaudin-Seiler B, Ciarametaro M, Dubois RW, Lee J, Fendrick AM. Reducing low-value care. Health Affairs. September 20, 2016. Accessed April 1, 2021. https://www.healthaffairs.org/do/10.1377/hblog20160920.056666/full/
11. Zafar HM, Bugos EK, Langlotz CP, Frasso R. “Chasing a ghost”: factors that influence primary care physicians to follow up on incidental imaging findings. Radiology. 2016;281(2):567-573. doi:10.1148/radiol.2016152188
12. Jarvik JG, Meier EN, James KT, et al. The effect of including benchmark prevalence data of common imaging findings in spine image reports on health care utilization among adults undergoing spine imaging: a stepped-wedge randomized clinical trial. JAMA Netw Open. 2020;3(9):e2015713. doi:10.1001/jamanetworkopen.2020.15713
13. Schwartz AL, Chernew ME, Landon BE, McWilliams JM. Changes in low-value services in year 1 of the Medicare Pioneer Accountable Care Organization Program. JAMA Intern Med. 2015;175(11):1815-1825. doi: 10.1001/jamainternmed.2015.4525
14. Ganguli I, Simpkin AL, Colla CH, et al. Why do physicians pursue cascades of care after incidental findings? a national survey. J Gen Intern Med. 2020;35(4):1352-1354. doi:10.1007/s11606-019-05213-1
15. Frakes MD, Gruber J. Defensive medicine: evidence from military immunity. National Bureau of Economic Research working paper No. 24846. July 2018. Accessed December 21, 2020. https://www.nber.org/system/files/working_papers/w24846/w24846.pdf
16. Mello MM, Kachalia A, Studdert DM. Medical liability — prospects for federal reform. N Engl J Med. 2017;376(19):1806-1808. doi:10.1056/NEJMp1701174
17. Levinson W, Roter DL, Mullooly JP, Dull VT, Frankel RM. Physician-patient communication. the relationship with malpractice claims among primary care physicians and surgeons. JAMA. 1997;277(7):553-559. doi:10.1001/jama.277.7.553
18. Colla CH, Kinsella EA, Morden NE, Meyers DJ, Rosenthal MB, Sequist TD. Physician perceptions of Choosing Wisely and drivers of overuse. Am J Manag Care. 2016;22(5):337-343.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Pervasiveness and Clinical Staff Perceptions of HPV Vaccination Feedback
November 11th 2024This article used regression analyses to quantify how clinical staff perceive provider feedback to improve human papillomavirus (HPV) vaccination rates and determine the prevalence of such feedback.
Read More